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Background:Malaria is an extremely devastating disease that continues to affect millions of people each year. A
distinctive attribute of malaria infected red blood cells is the presence of malarial pigment or the so-called
hemozoin. Hemozoin is a biocrystal synthesized by Plasmodium and other blood-feeding parasites to avoid the
toxicity of free heme derived from the digestion of hemoglobin during invasion of the erythrocytes.
Scope of review: Hemozoin is involved in several aspects of the pathology of the disease as well as in important
processes such as the immunogenicity elicited. It is known that the once best antimalarial drug, chloroquine,
exerted its effect through interferencewith the process of hemozoin formation. In the present reviewwe explore
what is known about hemozoin, fromhemoglobin digestion, to its final structural analysis, to its physicochemical
properties, its role in the disease and notions of the possiblemechanisms that could kill the parasite by disrupting
the synthesis or integrity of this remarkable crystal.
Major conclusions: The importance and peculiarities of this biocrystal have given researchers a cause to consider it
as a target for new antimalarials and to use it through unconventional approaches for diagnostics and therapeu-
tics against the disease.
General significance: Hemozoin plays an essential role in the biology of malarial disease. Innovative ideas could
use all the existing data on the unique chemical and biophysical properties of this macromolecule to come up
with new ways of combating malaria.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
Malaria is a disease caused by Plasmodium parasites, resulting in ap-
proximately one million deaths every year around the world. Regions
and countries affected by poverty are most at risk of infection. One of
the greatest obstacles in the control of malaria has been the spread of
drug resistance almost worldwide. Currently, the standard treatment of
uncomplicatedmalaria in these regions consists of artemisin-based com-
bination therapies (ACTs),while chloroquine combinedwith primaquine
is the treatment of choice for chloroquine-sensitive infections. For the
treatment of severe malaria there are two classes of drugs available:
the cinchona alkaloids (quinine and quinidine) and artemisin deriva-
tives (artesunate and artemether) [1]. Resistance to chloroquine and
sulfadoxine–pyrimethamine fueled the ongoing scourge of Plasmodium
falciparum, the principal cause ofmalariamorbidity andmortality in the
world. In response to the increased number of infections, the World
Health Organization (WHO) has recommended the use of combinatori-
al therapies that include artemisinin derivatives as first-line therapy.
Nevertheless, even combinations with new drugs have the potential
to create resistance [2–4]. Research efforts are needed to find alterna-
tive treatments for malaria that avoid the problem of drug resistance
altogether.
One approach for the development of new treatments againstmalaria
is to study the Plasmodium distinctive molecule hemozoin and to try to
target this vital pathway of the parasite [5]. Hemozoin (HZ) is a metabol-
ically crystallized byproduct of the digestion of hemoglobin by the para-
site during infection of the red blood cells (RBCs). The formation of
hemozoin from heme residues is common among diverse hematopha-
gous organisms without phylogenetic relation to Plasmodium spp, such
as Schistosoma mansoni and Rhodnius prolixus [6]. Since sequestration of
heme into hemozoin is an essential process for the survival of themalaria
and other apicomplexan parasites, this molecule has become an attrac-
tive target for new drugs that could interfere with the biocrystallization
of hemozoin and would help fight diseases caused by these pathogens,
especially malaria [7–10].
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2. Hemozoin synthesis
2.1. Hemoglobin degradation
Hemoglobin is the principal component of red blood cells, compos-
ing approximately 95% of the proteins of the cytosol, reaching a concen-
tration of about 5 mM inside the cytoplasm [11].
During the intra-erythrocytic stages ofmalaria infection, up to 80% of
the cytoplasm of the host is consumed. Although during the ring stage
some hemoglobin degradation is detectable, the major part of this pro-
cess takes place during the trophozoite and schizont stages, which per-
form most of the metabolic activity of the parasite [12].
The hemoglobin degradation process occursmostly inside the diges-
tive vacuole of the parasite (Fig. 1). These organelles in P. falciparum are
acidic structures with an estimated pH of 5.0 to 5.4 [13,14]. The acidic
pH in these vacuoles is maintained by a proton gradient activated by
anATPase pump. It is thought that the digestive vacuole is a vesicle ded-
icated almost exclusively to hemoglobin degradation because of the lack
of the characteristic lysosomal phosphatase and glycosidases present in
other organisms. Hemoglobin degradation was believed to play a vital
role as an amino acid source for malaria parasites because it has been
observed that they have a limited capacity to synthesize their own.
Some have alleged that the parasites do not need to degrade othermac-
romolecules to sustain growth and development because they obtain
most of the nutrients directly from the digestion of hemoglobin [15].
But, given that hemoglobin is a poor source ofmethionine, cysteine, glu-
tamine and glutamate, and completely lacks isoleucine, parasites must
be degrading hemoglobin for purposes other than just nutrition or de-
toxification. Such an idea was tested in experiments where parasites
were placed in a culturemedium that provided themwith the 20 essen-
tial amino acids; it was shown that the parasites were still degrading
hemoglobin [16]. Several studies demonstrated that some protease in-
hibitors block the proteolysis of hemoglobin, and the result was that
the parasite development was interrupted, even with all nutritional re-
sources available [17–20]. Therefore the idea of hemoglobin being
digested mainly for nutritional purposes was not completely accurate.
An equilibrium system exists inside the parasite between host hemo-
globin degradation, efflux of the amino acids produced by hemoglobin
degradation, and influx of extracellular amino acids and subsequent in-
corporation into parasite proteins. While the parasite grows and de-
velops, the amount of hemoglobin degradation increases but not the
amount of parasite protein: even though malaria parasites digest more
than 65% of the host cell hemoglobin, they only use approximately
16% of this digestion to synthesize proteins for their own needs [21].
The membrane of the infected erythrocyte becomes more permeable
to amino acids as it develops, allowing for large amounts of them to
exit from the cell [21]. Later findings evidenced that the parasite digests
the erythrocyte hemoglobin in order to prevent it from early lysis,
which could take place if the parasite did not offset the increase in cell
volume [22]. This colloid osmotic hypothesis was corroborated with
mathematical models, which accurately fit the experimental data [23].
Most of the enzymes implicated in the hemoglobin degradation path-
way have been elucidated. Two aspartic proteases (plasmepsins I and II)
and a cysteine (falcipain) protease have been isolated and purified from
the digestive vacuole of P. falciparum. All of these proteases function opti-
mally at a pH of around 5, coinciding with the digestive vacuole acidity
[24,25]. Aspartic proteases account for 60–80%, and cysteine protease for
20–40% of the globin-degrading activity of purified digestive vacuoles [11].
Plasmepsin I makes the initial attack between the α33Phe and 34Leu
residues of hemoglobin and then the subsequent cleavages take place else-
where. The 33–34 bond is located in a specific region that plays an essential
conformational role in the hemoglobin molecule, acting like a hinge in
the tetramer. Apparently, cutting the molecule in this specific site allows
for the uncoiling of hemoglobin, exposing other sites for later proteolytic
attacks by cysteine and aspartic proteases of the degradation pathway [25].
For the hemoglobin degradation process, the parasite needs both
plasmepsins I and II. The reasons for the parasite needing two different
enzymes for a single function are still unknown. In any case, different
enzymatic expression patterns of these molecules have been detected
along the intraerythrocytic stage of the parasite [26]. During the ring
stage only plasmepsin I is expressed, and its expression continues dur-
ing the following stages of the parasite. In contrast, plasmepsin II is
mainly expressed during the trophozoite stage, which is the most met-
abolically active. Not surprisingly, almost all of the host cytoplasm is
consumed during this stage. In fact, both enzymes are active during
the trophozoite stage and are necessary to fulfill the massive catabolic
processes taking place in this period of growth of the parasite [11].
In studies performed byMueller and colleagues, exploiting the differ-
ence in sensitivity of both plasmepsin enzymes to the plasmepsin inhib-
itor SC-50083, they determined their role in the survival of the parasites,
and the teamconcluded that blocking the activity of plasmepsin I leads to
the death of parasites. Surprisingly, although the amount of plasmepsin II
Fig. 1. Diagram of hemoglobin degradation and formation of hemozoin inside P. falciparum infected erythrocytes. Hemoglobin is degraded to obtain amino acids and to regulate osmotic
pressure, and the parasite converts the toxic heme part into harmless hemozoin inside the parasitophorous food vacuole. RBC: red blood cell; FV: food vacuole.
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is higher during the trophozoite stage than the amount of the enzyme
during the ring stage, this stage abundance was not enough to compen-
sate for the absence of plasmepsin I in the throphozoites [17].
There is some evidence for the possible involvement of a third
aspartic protease, but it has not been confirmed either by purification
or by cloning [27].
The last enzyme involved in hemoglobin degradation is a cysteine
protease called falcipain. Falcipain does not cleave the hemoglobinmol-
ecule unless it is previously denatured either by reducing conditions,
acid-acetone treatment, or previous plasmepsin cleavage [24].
Chugh et al. recently reported the presence of a protein complex of
about 200 kDa in the food vacuole of the parasite that is needed
for the processes of hemoglobin degradation but also for hemozoin
synthesis. This complex is formed by the most important enzymes in-
volved during these two important processes: falcipain 2, plasmepsin
II, plasmepsin IV, histo-aspartic protease and a protein called Heme De-
toxification Protein (HDP) [28]. The existence of this complex has been
proven by several techniques such as coimmunoprecipitation followed
by mass spectrometry, coelution from a gel filtration column and
in vitro protein interaction analyses [29].
2.2. Hemozoin biocrystallization
The proteolytic process of hemoglobin degradation releases free
heme that would be toxic to the malaria parasite. The lack of heme ox-
ygenase in Plasmodium spp, the enzyme present in all vertebrates and
responsible for the degradation of the hememoiety,means that the par-
asite must provide for another method of detoxification, which is
achieved by converting the heme monomer into the inert biocrystal
called malarial pigment or hemozoin.
α-Hematin (ferriprotoporphyrin IX), which is toxic to the parasite, is
released during hemoglobin digestion [30]. However, and most possibly
as a protection strategy, the parasite transforms α-hematin into
hemozoin (chemically identical toβ-hematin), amoleculewith paramag-
netic properties. The magnetic properties of this ferriheme were exten-
sively studied by Pauling et al. by the middle of last century [31,32]. By
determining the magnetic susceptibilities of ferriheme it was concluded
that it contains a five coordinate high spin trivalent iron compound [33].
It was shown that in this arrangement the iron atom is attached to the
four adjacent nitrogen atoms of the porphyrin, not by covalent bonds
but by ionic bonds. In ferriheme the iron is present essentially as Fe(III).
The term β-hematin was coined by Hamsik (in the 1920s) [34] for
sodiumbicarbonate insoluble hematin. The facts thatβ-hematins are in-
soluble in sodium bicarbonate solution, that hematin esters are not
transformed into β-hematin compounds, and that β-hematins are re-
converted into hemin esters by esterification indicate that the carboxyl-
ic acid groups of hematin are involved inβ-hematin formation. Lemberg
& Legge (1949) [35] used the term β-hematin to allude to the presence
of a specific linkage in which iron of one hematin unit is bound to the
propionic acid group of another; β-hematin can either be a cyclic
dimer or a linear polymer [5].
It is important to note that syntheticβ-hematin crystals can bemade
in vitro with the same NMR and X-ray diffraction pattern as parasitic
hemozoin by adding the whole trophozoite lysate to heme acidified to
a pH between 5 and 6 [36]. However, there are differences between
synthetic (sHZ) and natural hemozoin (nHZ). The size and shape of
synthesized β-hematin crystalsmay not be identical as a result of differ-
ences in the purification process used. While natural hemozoin is com-
posed of smaller crystals measuring between 50 and 500 nm, synthetic
β-hematin crystals can range from 50 nm to 20 μm, depending on the
solvent used to form them. This is an important consideration to take
into account, as different sized hemozoin crystals may possess diverse
immunomodulatory responses, as explained elsewhere [37].
Studies to elucidate the mechanism of hemozoin formation can be
divided into two main categories: First, those that investigated its for-
mation under entirely non-biological conditions; and a second group
of studies that focused on analyzing the formation of β-hematin in the
presence of biological material, either in the form of trophozoite ex-
tracts, histidine rich protein (HRP) or lipids.
The first group concentrated on β-hematin formation carried out in
acetate solution, and suggested that a complete β-hematin formation
was possible at a moderately low pH [38,39]. These observations led
to the proposal that the reaction might be spontaneous in the parasite,
without any initiator or catalyst.
Concerning the second group of studies, three important hypotheses
have been postulated [40]:
1. Hemozoin biocrystallization is an autocatalytic process: recent stud-
ies have obtained microscopic images of hemozoin crystals growing
on the surface of pre-existing hemozoin crystals [41].
2. Biocrystallization is due to the action of enzymes: this presupposes
the presence of proteins. One possible candidate is HRP1. This protein
is ingested by the parasite in the process of hemoglobin degradation
and it was demonstrated that it can promote in vitro hemozoin syn-
thesis [42], but the involvement of another HRP could not be ruled
out. In Plasmodium parasites there are many processes with a redun-
dancy. Examples are found in the invasion process [43,44] and in the
hemoglobin degradation process [45]. In the same way, there was
also evidence of common redundancy in the existence of at least
two HRPs that could be involved in hemozoin formation [42]. In
2007, E. Hempelmann convincingly discussed how the unfruitful
search for a heme polymerase responsible for forming hemozoin in
HZ-producing species ended up in the realization that hemozoin is
not a true polymer and thus established “biocrystallization” as the
best term to describe the process that forms hemozoin [5]. In fact, in
light of this, and of the observation that double mutants for HRPII
andHRPIII still formhemozoin [46], Egan concluded that HRP is prob-
ably not involved in hemozoin formation at all [47].
3. Biocrystallization is catalyzed by lipids: The third hypothesis attri-
butes hemozoin formation to the action of lipids [48–50]. With the
evidence obtained in recent investigations there is no doubt that
some lipids promote the formation of β-hematin crystals. The prod-
uct of this synthesis has been well characterized by spectroscopic
techniques [51,52]. These lipids have been described as a neutral
lipid blend (NLB) andmonopalmitoylglycerol (MPG), which are syn-
thesized by the parasite and packed in the FV. These lipids associated
with the FV are thought to come from the digestion of the transport
vesicles. It was shown that these lipids are highly efficient at
converting Fe(III) PPIX to β-hematin with yields at or above 80%
[53] just as was suggested by Sullivan in 2005 [54].
While several lines of evidence point to involvement of acylglycerol
lipids in the nucleation process [53,55,56], a recent study focused on the
location andorientationof hemozoin crystals. To address this, they applied
cryogenic soft X-ray tomography and three-dimensional electron micros-
copy. They found that hemozoin nucleation occurs in an orientedmanner
at the inner surface of the digestive vacuole, with crystallization, surpris-
ingly, occurring in the aqueous phase rather than in the lipid phase [57].
Finally, concerning the hemozoin formation processes, and as men-
tioned in the hemoglobin degradation section, Rathore et al. identified
and characterized another protein that converts heme into hemozoin
in a very powerful manner. This protein is the HDP [28].
To conclude, at present it is still unclear which and if any of these
mechanisms is actually involved in hemozoin crystallization processes
in vivo. More studies in this direction are needed to elucidate the com-
plete mechanism of HZ production in Plasmodium parasites.
3. Hemozoin structure
The structure of hemozoin has been elucidated by X-ray diffraction,
infrared spectroscopy, Raman spectroscopy and chemical synthesis. The
moleculewas first determined to consist of anunusual polymer of heme
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groups linked by bonds between the oxygen from the carboxylate of
one heme and the central ferric ion of the next heme. This unusual link-
age allows the heme units to be aggregated into an ordered insoluble
crystal (Fig. 2), representing a unique way of heme processing [58].
In the early nineties, Slater et al. used purified hemozoin and the
hemozoin forming unit (hematin) to address the hemozoin structure
through differences in solubility and spectroscopic properties. This
was a better way to elucidate the structure because the one for hematin
was known, and a comparison of the behavior of these two molecules
could infer similarities and differences. First, hematin is soluble inweak-
ly basic bicarbonate or borate buffers and in aprotic solvents. In contrast,
hemozoin is insoluble in both kinds of solvents [58].
The solubility difference could be explained if there is amodification
in the environment surrounding the carboxylate side groups and the
iron of heme in hemozoin. Concerning the hemozoin and hematin IR
spectra, it has been determined that they are also quite different.
Hemozoin is more sharply resolved than hematin, suggesting a reduc-
tion in the hydrogen bonding. Also, the IR spectrum of hemozoin
contains additional major features at 1664 and 1210 cm−1 absent in
the spectra of hematin. As absorbances between 1720 and 1650 cm−1
indicate C_O stretching, this suggests the presence of only one bond
between the carboxylate side chain and the metal iron in hemozoin.
Solubility data and IR spectra of hemozoin lead to a possible struc-
ture of hemozoin where it displays a direct coordination between a car-
boxylate of one heme and the iron of the following [58].
Additionally, since axial Fe\C (O) coordinations produce very
strong C\O stretching frequencies around 1900 cm−1 [59], and they
are absent in the IR spectra, a direct iron-carbon linkage can be ruled
out in the structure of hemozoin. This fact, in turn, led researchers to
propose that the oxygen and carbon stretch probably belongs to a car-
boxylate group which has one oxygen directly coordinated to the cen-
tral iron of the molecule. This statement has been evidenced by
infrared and Raman spectroscopy [60].
β-Hematin can either be a polymer or a dimer. Electrophoretic stud-
ies were done in 1993 to distinguish between the two models; a poly-
mer would produce a ladder after separation by SDS electrophoresis
and a dimer only a single band: a ladder was never found [46]. The ines-
capable conclusion was that β-hematin found in P. falciparum is com-
posed of dimers.
Pagola et al. finally elucidated the structure of β-hematin using high
resolution X-ray powder diffraction data and analyzed it with a simulat-
ed annealing algorithm. They solved the crystal structure by positioning
the molecule and finding the torsion angles that give the best agree-
ment between experimental and calculated powder diffraction profiles.
In all of the combinations made by the software, the molecules were
paired into dimers by iron–oxygen bonds. Thus, the idea that hemozoin
is just a polymer was invalidated. It is now well known that it is com-
posed of a series of molecules linked into dimers through reciprocal
iron-carboxylate bonds to the propionic side chains of each porphyrin,
and that the dimers form chains linked by hydrogen bonds in the crystal
[61] (Fig. 3). This was concluded through photoacoustic spectroscopy
(discussed later in this review) [62] and corroborated more recently
by using β-hematin DMSO solvate, being this the first Fe(III) PPIX
model of hemozoin studied by single crystal X-ray diffraction [63].
About the spin state of the iron center in hemozoin, the definite con-
clusions were given by Sienkiewicz et al. in 2006 with multi-frequency
high-field electron paramagnetic resonance (HFEPR) studies. Based on
previous data of magnetic susceptibility and Mossbauer spectroscopy,
the presence of a high spin iron seemed very likely, but there were
still ambiguities in the interpretation of the data, and they persisted
until the analysis, done by the team of Sienkiewicz using the same tech-
nique, showed that the spectra obtained for hemozoin and synthetic
β-hematin can only correspond to a high spin Fe III (S = 5/2), finally
giving closure to this issue [33].
4. Hemozoin immunomodulatory action
Phagocytes are the first line of defense against malaria infection in
non-immune patients. There is a relationship between their capacity
for phagocytosis and the parasite stage. Macrophages ingest more
avidly RBCs infected with trophozoites and schizonts, rather than
rings of P. falciparum. It is thought that, as the red blood cell membrane
Fig. 2.Atomic forcemicroscopy (AFM) image of P. falciparum hemozoin. A culture of blood
stage P. falciparumwas examinedwith a Nanowizard, JPK Instrument AG, Germany. Anul-
trasharp noncontact AFM-tip (NSG10, ATOS GmbH, Germany)was used and the AFMwas
operated in the instrument's intermittent contact mode (Image by Lorena Coronado at
Volker Deckert Laboratory, Institute of Photonic and Technology, Jena, Germany).
Fig. 3. Chemical arrangement of hemozoin. A)Monomers of hemozoinwith iron, shown in
gray, will join to form a dimer. B) Crystal moiety with the dimers forming H-bonds with
oxygen atoms (red) of contiguous ones.
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containing mature staged parasites has more alterations due to the size
of the parasite, it is better recognized by IgG and complement compo-
nents [64]. In humans, the three most common locations where the
macrophages that ingest hemozoin can be found are: the spleen, liver
and bone marrow [65–67]. In Plasmodium, hemozoin was considered a
non-toxic form of digested heme from the host cell [36,68]. However,
it can be seen now that hemozoin is involved in other aspects of the dis-
ease, affecting the macrophages which ingest it and contributing to the
pathophysiology of the disease [69–75]. Hemozoin is released into cir-
culation during erythrocyte lysis. After schizont rupture, crude
hemozoin, composed of aggregated heme and a variety of attached
components of parasite andhost origin (lipids, lipid derivatives and pro-
teins) is avidly taken up by phagocytes, both in vivo and in vitro [76].
Macrophages that have ingested infected RBCs with parasites in the
ring stage are able to degrade hemoglobin rapidly and can repeat the
phagocytic cycle. In contrast, when the parasites ingested are in a ma-
ture stage the macrophages are unable to degrade hemoglobin or con-
tinue with the normal phagocytic cycle [77]. These macrophages
appear to lose all functionality regarding the ingestion of opsonized,
damaged erythrocytes or the killing of ingested bacteria, fungi or
tumor cells [78,79]. It has been suggested that this toxic effect inmacro-
phages that have ingested latter stages of Plasmodium parasites is due to
the HZ crystals causing a permanent damage in the normal function of
these cells [77]. HZ is rapidly ingested by phagocytes and induces the
production of several pro-inflammatory mediators such as IL-1b and
TNFα and is also associated with cytokine production inmurinemodels
[80]. Studies in both human and murine macrophages, in vitro and
in vivo, show a thermal deregulation, associated with in vivo fever,
after injecting chemically synthetized HZ [80]. It should be stated, how-
ever, that Jaramillo et al. reported that similar immune responses with
native and synthetic hemozoin can be obtained only after verifying
that the crystals of the synthetic HZ (sHZ) resemble those of native HZ
(nHZ) in size, morphology, and physicochemical characteristics
[81,82]. Moreover, the extraction method utilized to isolate nHZ for im-
munomodulatory experiments must be carefully taken into account
since host proteins, lipids and even DNA attached to the crystals might
withstand the process of extraction and induce immune reac-
tions [83,84] that differ from those caused strictly bynHZ. It is important
to note, though, that nHZ is usually attached to other material also
in vivo, with various immunological consequences. For example, host fi-
brinogen (FG) is present and stably bound to nHZ from plasma cultured
parasites, and is responsible for the rapid stimulation of reactive oxygen
species (ROS), due to the interaction of FG with Toll Like Receptor 4
(TLR4) and integrin CD11b–CD18 [85]. The role of the TLRs in the im-
mune reaction to malaria is discussed further down.
Millington et al. demonstrated in vitro and in vivo, that malaria par-
asites induce failure in the function of dendritic cells. This, subsequently,
causes a decline in T cell activation that would normally modulate het-
erologous and infection-stimulated immunological reactions [86–90].
Thus, hemozoin affects directly the normal function of the adaptive im-
mune response. Some have argued that the decline in functionality of
phagocytes that have ingested hemozoin could also be due to the gener-
ation of reactive oxygen species inside the white blood cell [75]. HZ has
the ability to become a powerful generator of radicals due to its unique
sequestration of the ferric heme in a paracrystalline compact form.
Crude hemozoin, loaded in vitro to murinemacrophages, and to macro-
phages isolated from malaria infected murine livers, is not capable of
generating radicals by itself but it can do so in the presence of a lipid
component, specifically unsaturated fatty acids; lipid removal totally
abolishes radical production [71]. A lack of activation of nitric oxidase
synthase (NOS) in human monocytes when challenged with HZ, in
contrast with the upregulation found in murine macrophages, has
been reported [91]. This observation was contrary to findings suggest-
ing that inducible NOS (iNOS) upregulation does take place in humans
and could even confer protection againstmalaria [92,93]. A careful anal-
ysis of the data published on this matter reveals that experimental
conditions might influence the outcome of the investigation. This fact,
in conjunctionwith the natural differences found between the two spe-
cies, should alert researchers to the need for caution when inferring
similar immunomodulatory reactions through extrapolation of results
obtained in murine models to humans.
The parasitic food vacuole has a specific pH and environment that
promotes peroxidation. Parasitized RBCs and hemozoin contain large
amounts of esterified monohydroxy derivatives of polyunsaturated
fatty acids (OH-PUFAS) that can result from lipid peroxidation of
polyenoic fatty acids or by the action of a lipoxygenase. Schwarzer
et al. pointed out that since mature RBCs do not have lipoxygenases
(LPO) and no LPO isoform or activity has been found in the sequence
of P. falciparum or the parasite, respectively, OH-PUFAS are probably
the end product of a lipid peroxidation catalyzed by heme, a process al-
ready described previously for this molecule [94]. Specific components
of this lipid fraction, present in infected RBCs and hemozoin, are then re-
sponsible for the decline in the oxidative burst in monocytes. In conse-
quence, they contribute to hemozoin-induced toxicity to phagocytes
after ingestion, which leads to a failure in the immune response [76].
Malarial anemia is characterized by the destruction of infected as
well as uninfected RBCs. This massive destruction leads to a decrease
in erythroid precursors and erythropoiesis inhibition, usually resulting
in the death of the patient. Hemozoin is thought to be related to this
anemia phenomenon as well as to the production of inflammatory me-
diators such as tumor necrosis factor (TNF-α) in murine models. In
2004, Arese et al. demonstrated that supernatants of nHZ, nHZ fed
monocytes, and 4-hydroxynonenal (HNE), generated through lipid per-
oxidation, inhibited progenitor growth [84]. This observation indicates
that toxic molecules generated by HZ may play a direct role in erythro-
poiesis inhibition. This was confirmed by another group in 2006 [95].
They showed in vitro that isolated HZ, after a process of delipidation
and in complete absence of TNF-α, inhibited erythropoiesis. They also
showed in children with malaria that monocytes containing HZ
inhibited erythropoiesis independently from circulating cytokines.
They also found indications of apoptosis in erythroid cells in vitro as
an effect of HZ treatment. HZwas found to enhance the levels of cleaved
caspases 8 and 3 and also to disturb the membrane potential of mito-
chondria. They concluded that HZ has an impact on the extrinsic apo-
ptotic pathway in erythroid cells. These results were validated and
reconfirmed in vitro by other studies where HNE was identified as an
erythropoiesis inhibitory molecule generated by HZ lipid peroxidation
and alteration of critical proteins of the cell cycle [96,97].
Another important group ofmolecules involved in the innate immune
responses to Plasmodium infection is the Toll-like receptors, which recog-
nizemalaria parasites and derivatives [98]. Coban et al. studied the role of
TLRs and their signaling molecules in cerebral malaria pathogenesis.
Their results strongly suggest that immune response via TLR2, TLR9 and
MyD88 (an essential adaptor molecule for most TLRs) is closely involved
in this clinical complication of malaria [99]. Coban's findings have been
corroborated in various ways. It was recently demonstrated that TLR9
and MyD88 are crucial for the development of protective immunity to
malaria [100,101] to the point of them being considered as possible adju-
vants in malaria vaccines [37]. Also, polymorphisms in TLR4 predispose
patients to cerebral malaria [102] and TLR7 plays a central role in early
immune activation during malaria infection as well [103].
Clearly, hemozoin release plays a very crucial role in thepathology of
malaria, especially in what concerns the immunological response,
which evidences that hemozoin is much more than just a by-product
crystal from hemoglobin degradation.
5. Hemozoin as drug target
5.1. Chloroquine mechanism of action
Since hemozoin crystallization is vital for malaria parasite survival
this process stands out as an attractive target in the search for new
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antimalarial drugs [104]. The postulated mechanisms by which these
drugs would act on hemozoin differ subtly. The best studied one has
been that of chloroquine (CQ).
A first line drug against malaria for more than four decades up to the
mid 1980s, chloroquine is thought to act via its action in the digestive
vacuole related to the inhibition of hemozoin formation. It has been
demonstrated that there is a relationship between the HZ inhibition
effect and the antiplasmodial IC50 activity of chloroquine. Also, CQ-
mediated parasite death is directly related to hemozoin inhibition
[105]. And although this drug kills parasites in ring better than in tro-
phozoite stages [106], there is evidence that in trophozoite cell extracts,
chloroquine also inhibits hemozoin crystallization [36].
Chloroquine enters into the parasitic digestive vacuole through
simple diffusion. The acidic pH of the vacuole (pH ~ 5), however, pro-
duces a diprotonation of the drug and in this form the molecule cannot
diffuse back through the membrane, remaining trapped inside the vac-
uole. There, diprotonic CQ interferes with the parasite detoxification
process by inhibiting heme transformation into hemozoin. The accumu-
lation of heme causes severe damage to the parasite, leading to its death
[107].
Based on what little was known about the mechanism of action of
CQ, several studies focused on testing its role as a possible inhibitor of
hemozoin (ferriprotoporphyrin IX) crystallization [36,108,109]. They
concluded that chloroquine does inhibit hemozoin formation by inter-
fering in its assembly, be it initiated by hemozoin or by trophozoite ex-
tracts [36,109,110]. This hypothesis is now accepted as the mechanism
of action of 4-aminoquinoline antimalarials. Later, in experiments per-
formed by Sullivan et al., it was demonstrated that CQ inhibited the
HRP II mediated synthesis of hemozoin [42], which is consistent with
the proposed mechanism of action of this drug on heme crystallization.
Wood et al. performed a study using resonance Raman spectroscopy
to monitor the effects of CQ treatment on cultures of P. falciparum tro-
phozoites. They found that some characteristic bands of HZ were re-
duced in their intensity in the CQ treated cells. These intensity
changes were attributed to intermolecular drug binding of the CQ in
complex with the ferriprotoporphyrin IX dimer units. They postulated
that CQ binds via π–π interactions (attractive, noncovalent interactions
between aromatic rings) between adjacent porphyrins, thereby
disrupting the hemozoin aggregate and reducing excitonic interactions
between adjacent hemes [111].
While it had been generally accepted that heme was the target for
chloroquine, there was no direct evidence, until recently, linking the in-
hibition of hemozoin formation to an increase in the amount of free
heme molecules in the parasite cytoplasm when treated with chloro-
quine. Similar to CQ, quinine was found to inhibit heme detoxification
within the food vacuole resulting in the inhibition of hemozoin
biocrystallization [112]. With the use of sophisticated technology the
obvious was confirmed. X-ray diffraction was used to corroborate that
different concentrations of both chloroquine and quinine decrease the
rate of hemozoin formation [63]. Then measurements of Fe(III)heme-
pyridine using transmission electron microscopy were able to confirm
the link between the decrease in hemozoin formation and an increase
of toxic free heme in the parasite [112].
Few years ago it was thought that CQ could inhibit the peroxidative
degradation of heme, contributing to the building-up of toxic
membrane-associated heme molecules that would end up destroying
the parasite membrane [113]. But Mossbauer studies demonstrated
that there is a minor role of heme degradation in the parasite, so it
seems unlikely that this is the mechanism of action of antimalarials
such as CQ [114].
Unfortunately, malaria parasites have developed resistance to chlo-
roquine in most parts of the world [3]. The key to this resistance lies
in a specific mutation in a chloroquine transporter protein, PfCRT. This
protein is present in the parasitic digestive vacuole and it is responsible
for the efflux of the diprotonic chloroquine, avoiding its accumulation in
the organelle [115,116].
The role of this protein in CQ resistance has been shown by several
studies and was clearly demonstrated on a recent report by Martin
et al. [117]. In this study, the transporter protein was expressed in the
surface of Xenopus oocytes. The transporter activity of the sensitive
and resistant PfCRTversionswasmeasuredmaking sure that the chloro-
quine was protonated. They demonstrated that chloroquine resistance
was directly related to the transport of the protonated form of the
drug outside of the membrane. They found that the resistance related
to this protein lies in specific mutations in only two amino acids of the
entire protein sequence: lysine for threonine 76 and arginine for serine
163. In sensitive strains, threonine and serine contribute a positive
charge to the active site of PfCRT, and this results in a diminished trans-
porter activity. The single change of threonine 76 by lysine in themutat-
ed PfCRT is not enough to confer resistance, but together with the
argininemutation, it renders the parasite resistant to this amino quino-
line [117]. The exactmechanism bywhich the PfCRTworks as the trans-
porter of CQ is still being studied. In fact, there is a debate aboutwhether
the mutated PfCRT acts as a carrier or as a channel [115,118]. What is
known is that some drugs can rescue the effect of the PfCRT-mutated
parasites in vitro. Verapamil and amantadine increase the sensitivity of
CQ-resistant parasites to the drug [117]. The most effective inhibitors
of resistance in these parasites were particularly endomorphin-1 mole-
cules (endogenous opioid peptides) such as quinine [119].
The thorough study of these mechanisms is very relevant in the de-
sign of new drugs that target hemozoin and/or to modify the existing
chloroquine molecule to circumvent the resistance of the parasites. A
drug like chloroquine is effective, inexpensive and has a low toxicity.
Rescuing its efficacy would be especially important to control the dis-
ease in regions where malaria is endemic and access to more expensive
drugs is very limited.
6. Biophysical properties of hemozoin
As is the case with CQ, the greatest problem in the control of malaria
has been the development of drug resistance to the most common and
less expensive drugs currently used.
The need to find new alternatives to diagnose and treat malaria is
enormous. Some groups have turned to the biophysical properties of
hemozoin for answers [120–124].
A detailed knowledge of these properties should be basic to the dis-
covery of new ways of taking advantage of this molecule in the fight
against malaria.
6.1. Electromagnetic properties
Hematin has several electromagnetic properties that have been
exploited to detect, separate, disrupt, or kill the malaria parasite.
These include:
• Paramagnetism
• Optical dichroism
• Optical non-linearity.
Paramagnetic substances have a magnetic moment only in the
presence of an applied magnetic field. Paramagnetism in hemozoin
arises from the unpaired electrons of the Fe3+ species of iron. When
an external field is present, the random unpaired spins line up to en-
hance the field. When the applied field is removed these unpaired
spins are rapidly randomized by thermal agitation.
The iron in hemozoin has a direct current (DC) magnetic molar sus-
ceptibility (Xmol) of 11.0 × 10−3 cm3 mol−1 [125]. Since the measure-
ments in Hackett were adjusted to 298 K (in CGS units), the effective
magnetic moment (μeff) per iron is
μeff ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
3k
NμB
2
ffiffiffiffiffiffiffiffiffiffiffiffi
TXmol
ps
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where k is the Boltzmann's constant, N is the Avogadro's constant, T is
the temperature, and μB is the Bohr magneton. Thus, moment μeff per
iron is approximately 5.1 Bohr magneton units.
The chemical formula for the β-hematin dimer is C68H60N8O8Fe2
with a molar mass of 1228.9495 g/mol. Based on the basic repeating
unit makeup of the crystal (crystal unit cell) dimensions [40], the unit
cell volume is 1.416 × 10−21 cm3. The volume of a mole of hemozoin
crystal without voids or imperfections would be 852 cm3. The density
of β-hematin is therefore 1.44 g cm−3.
With the molar volume known, the molar susceptibility can be con-
verted to volumetric units. Molar susceptibility is related to volumetric
susceptibility, Xv, by
ρXmol
M
¼ Xv
where ρ is density, andM is the molar mass.
This calculation leads to an average SI volumetric magnetic suscepti-
bility of Xv = 320 × 10−6 for the solid, perfect hemozoin crystal.
Thismagnetic susceptibility is very weakwhen compared to a ferro-
magnetic material, but relative to other paramagnetic materials,
β-hematin shows the paramagnetic effect strongly.
Paramagnet Xv · 106
β-Hematin 320
Tungsten 68
Cesium 51
Aluminum 22
The paramagnetism of β-hematin has been exploited a number of
ways, the most common being a method for separating infected red
blood cells from uninfected cells [126]. Paramagnetic hemozoin, like
any paramagnet, is attracted up a magnetic gradient toward the pole
of a strong permanent magnet [127].
Another useful electromagnetic property of hemozoin is its optical
dichroism. The anisotropic crystal structure of hematin (i.e. directionally
dependent) leads to anisotropy in its refractive index, causing light to
propagate differently through the crystal, depending on the propaga-
tion direction relative to the crystal lattice. A system that exploits both
the paramagnetism of hemozoin and its dichroism was developed for
detecting malaria infections [128,129]. A very strong magnetic field
can orient the hemozoin crystals within the digestive vacuole of live
parasites. Hemozoin crystals can be oriented to amagnetic field because
they are shaped as rods, rather than spheres, and as rods they posses
shape anisotropy, making the magnetic susceptibility larger (by about
a factor of 2) along the long “easy” axis of the crystal. This anisotropy
leads to an orienting torque that tends to align the easy axis with the
field. Because of the viscosity of the surrounding fluid, crystal orienta-
tion takes some time to respond. The response time determines the
highest frequency of magnetic fluctuation that can orient the crystals.
The magnetic orientation response times that appeared to the au-
thors as “near instantaneous” were achieved [129], but close examina-
tion of the data suggests that the response time was actually near
100 μs for an applied field of 1 T, implying response up to frequencies
of the order of 10 kHz.
This empirical observation of magneto-optical response time is con-
sistentwithwhat physics calculates [130]. Indeed the π/4 rotational ori-
entation time constant for hemozoin is of the order of 100 μs, assuming
a nano-scale hemozoin paramagnetic rod with dimensions typical for
hemozoin crystals (500× 300× 100 nm) oriented by a 1 teslamagnetic
field in the rheology (plastic-like flow) of the food vacuole.
This orientation effect has led some authors [131] to hypothesize that
rotatingmagneticfields could potentially disrupt the biocrystallization of
hemozoin. Although strong fields can spin hemozoin crystals, and per-
haps impede crystallization, moderate magnetic fields do not induce
enough torque on the crystals to overcome the rotational diffusion
caused by natural thermal agitation. Magnetic torque is proportional to
the magnetic field magnitude squared, so more moderate magnetic
fields have dramatically less effect on hemozoin. For example, a field of
1 mT, equivalent to a common refrigerator magnet, would generate a
million times less torque on a hemozoin crystal than would a 1 tesla
field. The weaker field would be unable to orient the hemozoin against
thermal diffusion. The requirement of a strong magnetic field to over-
come thermal rotational diffusion is evidence against the hypotheses of
direct mechanical action on paramagnetic hemozoin by relatively weak
magnetic forces in non-thermal RF, microwave, and optical electromag-
netic wave exposures.
Another electromagnetic property of hemozoin that has been
exploited is its non-linearity. A strong IR illumination was shown to in-
duce a third-harmonic emission in the ultra-violet wavelengths [132].
This UV emission has enough energy per photon to kill nearby cells.
Since the fundamental IR does not damage cells, only cells that contain
the optically non-linear hematin are targeted.
6.2. Photoacoustic properties
Very recently there have been studies that suggest that hemozoin
might have other physical properties that could be exploited for diag-
nostic or other innovative applications in the future.
A photoacoustic spectrum of amaterial sample is obtained by illumi-
nating the samplewith intense light andmeasuring the resulting acous-
tic vibrations in the material at different frequencies. This spectrum can
be used to identify the absorbing components of the sample, and there-
by detect tiny alterations in its composition.
First tried by Balasubramanian [62], photoacoustic stimulation has
been used to study the malaria parasites. Simulation results [133] sug-
gest that intraerythrocytic stages of malarial parasite may be assessed
using a photoacoustic spectroscopy technique. If confirmed empirically,
this technique could lead to an inexpensive detection and assay sensor
for infected blood.
Interestingly, a variation of flow cytometry named photoacoustic
flowmetry, where nanosecond laser pulses are aimed at the sample
generating ultrasonic signals, has had effects on the absorption of elec-
tromagnetic frequencies by hemozoin and in some of its physical
properties [134].
7. Conclusion
Malaria is a very complex disease. Its eradication must arise from a
concerted effort to gain control over the causative agent and vectors,
and success in creating awareness on how to best prevent the disease
within the population that is at risk.
Science, with the convergence of biochemistry, biophysics, and engi-
neering could make the most out of this peculiar crystal called
hemozoin. Given the current state of malaria in theworld, withmillions
of people succumbing annually to the disease, while resistance to the
most common and cheapest drugs keeps developing, hemozoin could
be key in the search for more sensitive diagnostics and/or alternative
therapeutics to decrease both the morbidity and mortality rates of this
scourge. Hemozoin is a uniquemolecule, a distinguishing trait of malar-
ia parasites and other blood-feeding organisms. Its unique features
should, and certainly will be exploited to make it a game-changer in
the fight against this devastating disease.
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